

091-22967A

For Internal Use Only  
Sec File No. 9-

Submit 1 Original  
and 9 Copies

OMB APPROVAL  
OMB Number: 3235-0504  
Expires: July 31, 2016  
Estimated average burden  
hours per response. . . . 3.60

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 19b-4(e)

Information Required of a Self-Regulatory Organization Listing and Trading a New  
Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934

SEC

READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM Mail Processing

Section

SEP 18 2017

Part I Initial Listing Report

Washington DC

1. Name of Self-Regulatory Organization Listing New Derivative Securities Product:  
Bats EDGA Exchange, Inc.

2. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):  
See Attached.

3. Class of New Derivative Securities Product:  
See Attached.

4. Name of Underlying Instrument:  
See Attached.

5. If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based:  
See Attached.

6. Ticker Symbol(s) of New Derivative Securities Product:  
See Attached.

7. Market or Markets Upon Which Securities Comprising Underlying Instrument  
Trades: See Attached.

8. Settlement Methodology of New Derivative Securities Product:  
Trades Locked in at Exchange and settled at NSCC.

9. Position Limits of New Derivative Securities Product (if applicable):  
Not Applicable.



17003536

RECEIVED  
2017 SEP 19 AM 11:29  
SEC / TM

Part II Execution

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form: Anders Franzon

Title: SVP, Associate General Counsel

Telephone Number: 913-815-7154

Manual Signature of Official Responsible for Form:

Date: September 15, 2017

Section	19b-4
Rule	19b-4(e)
Public Availability:	SEP 18 2017

ATTACHMENT TO FORM 19b-4(e)  
 FOR NEW DERIVATIVE SECURITIES PRODUCTS ("NDSPs") TRADED ON BATS EDGA EXCHANGE, INC.  
 COMMENCING ON SEPTEMBER 11, 2017

<u>(6) Ticker Symbol</u>	<u>(2) Type of Issuer of NDSP</u>	<u>(3) Class of NDSP</u>	<u>(4) Name of Underlying Instrument</u>	<u>(7) Market(s) upon Which Securities Comprising Underlying Instrument Trades</u>	<u>(5) Broad or Narrow</u>
BAR	Trust	Investment Company Units	Fractional undivided beneficial interest in the Trust	World	Narrow
BBC	Trust	Investment Company Units	Virtus LifeSci Biotech Clinical Trials ETF is based on LifeSci Biotechnology Clinical Trials Index	U.S.	Broad
BBP	Trust	Investment Company Units	Virtus LifeSci Biotech Products ETF is based on LifeSci Biotechnology Products Index	U.S.	Broad
FLMI	Trust	Investment Company Units	Tax-free securities	U.S.	Broad
FLMB	Trust	Investment Company Units	Tax-free securities	U.S.	Broad



SEC  
Mail Processing  
Section

SEP 18 2017

Washington DC  
412

September 15, 2017

Ms. Claudette Ransom  
Mail Stop 6628  
Securities and Exchange Commission  
100 F Street, N.E.  
Washington, DC 20549

RE: Form 19b-4(e) - Bats EDGA Exchange, Inc.

Ms. Ransom,

On behalf of Bats EDGA Exchange, Inc., enclosed please find one (1) executed Form 19b-4(e) and 9 copies. The enclosed Form 19b-4(e) contains information regarding five (5) derivative securities products that commenced trading on Bats EDGA Exchange on September 11, 2017. Please contact me if you have any questions in connection with this matter.

Sincerely,

Anders Franzon  
SVP, Associate General Counsel  
913.815.7154

SEC/TM

2017 SEP 19 AM 11:29

RECEIVED